Search Results

There are 54681 results for: content related to: The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor–induced hepatic lipotoxicity in mice

  1. You have free access to this content
    Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

    British Journal of Clinical Pharmacology

    Volume 73, Issue 5, May 2012, Pages: 758–767, Chao Zhang, Paolo Denti, Eric Decloedt, Gary Maartens, Mats O. Karlsson, Ulrika S. H. Simonsson and Helen McIlleron

    Version of Record online : 5 APR 2012, DOI: 10.1111/j.1365-2125.2011.04154.x

  2. Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine

    The Journal of Clinical Pharmacology

    Volume 46, Issue 7, July 2006, Pages: 758–767, P. G. Rolf, Dr van Heeswijk, Mr Marc Bourbeau, Ms Pearl Campbell, Ms Isabelle Seguin, Mr Bobby M. Chauhan, Dr Brian C. Foster and Dr D. William Cameron

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006288733

  3. You have free access to this content
    Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir

    British Journal of Pharmacology

    Volume 160, Issue 5, July 2010, Pages: 1224–1233, RAB van Waterschoot, R ter Heine, E Wagenaar, CMM van der Kruijssen, RW Rooswinkel, ADR Huitema, JH Beijnen and AH Schinkel

    Version of Record online : 22 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00759.x

  4. You have free access to this content
    Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir

    Basic & Clinical Pharmacology & Toxicology

    Volume 117, Issue 5, November 2015, Pages: 306–315, Paolo Fagone, Katia Mangano, Cinzia Quattrocchi, Eugenio Cavalli, Santa Mammana, Giuseppe A.G. Lombardo, Vincenzo Pennisi, Mai-Britt Zocca, Mingzhu He, Yousef Al-Abed and Ferdinando Nicoletti

    Version of Record online : 25 MAY 2015, DOI: 10.1111/bcpt.12414

  5. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 6, June 2011, Pages: 2508–2515, Rob ter Heine, Robert A. B. Van Waterschoot, Ron J. Keizer, Jos H. Beijnen, Alfred H. Schinkel and Alwin D. R. Huitema

    Version of Record online : 29 DEC 2010, DOI: 10.1002/jps.22457

  6. The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 51, Issue 2, February 2011, Pages: 237–242, Dr Ivy Song, Dr Sherene S. Min, Ms Julie Borland, Ms Yu Lou, Dr Shuguang Chen, Dr Parul Patel, Dr Toru Ishibashi and Dr Stephen C. Piscitelli

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010371113

  7. Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 1, July 2008, Pages: 75–82, C Wyen, U Fuhr, D Frank, RE Aarnoutse, T Klaassen, A Lazar, A Seeringer, O Doroshyenko, JC Kirchheiner, F Abdulrazik, N Schmeisser, C Lehmann, W Hein, E Schömig, DM Burger, G Fätkenheuer and A Jetter

    Version of Record online : 9 JAN 2008, DOI: 10.1038/sj.clpt.6100452

  8. Thermodynamics of Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs—Impact of a Second Drug on the Solution Phase Behavior and Implications for Combination Products

    Journal of Pharmaceutical Sciences

    Volume 104, Issue 8, August 2015, Pages: 2583–2593, Niraj S. Trasi and Lynne S. Taylor

    Version of Record online : 8 JUN 2015, DOI: 10.1002/jps.24528

  9. Interactions Between Amprenavir and the Lopinavir-ritonavir Combination in Heavily Pretreated Patients Infected with Human Immunodeficiency Virus

    Clinical Pharmacology & Therapeutics

    Volume 75, Issue 4, April 2004, Pages: 310–323, Anne-Marie Taburet, Gilles Raguin, Clotilde Le Tiec, Cécile Droz, Aurélie Barrail, Isabelle Vincent, Laurence Morand-Joubert, Geneviève Chêne, François Clavel and Pierre-Marie Girard

    Version of Record online : 8 APR 2004, DOI: 10.1016/j.clpt.2003.12.013

  10. Pharmacokinetics and Safety of the Lopinavir/Ritonavir Tablet 500/125 mg Twice Daily Coadministered With Efavirenz in Healthy Adult Participants

    The Journal of Clinical Pharmacology

    Volume 52, Issue 8, August 2012, Pages: 1248–1254, Juki Ng, Yi-Lin Chiu, Walid Awni, Barry Bernstein, Sonja J. Causemaker and Cheri E. Klein

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011410568

  11. Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus–Coinfected Subjects With Hepatic Impairment

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 265–274, Dr Joanna Z. Peng, Dr Federico Pulido, Ms Sonja J. Kemmis Causemaker, Ms Jianling Li, Dr Alicia Lorenzo, Dr Concepción Cepeda, Dr Juan A. García Cabanillas, Dr Barbara DaSilva, Dr Scott C. Brun and Dr José Arribas

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005284853

  12. Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers

    The Journal of Clinical Pharmacology

    Volume 53, Issue 2, February 2013, Pages: 202–210, Monika Schöller-Gyüre, Thomas N. Kakuda, James Witek, Sophie H. Akuma, Goedele De Smedt, Kurt Spittaels, Veerle Vyncke and Richard M.W. Hoetelmans

    Version of Record online : 24 JAN 2013, DOI: 10.1177/0091270012445205

  13. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model

    Journal of Pharmaceutical Sciences

    Volume 99, Issue 2, February 2010, Pages: 626–631, Kevin W. Garren, Sibtain Rahim, Kennan Marsh and John B. Morris

    Version of Record online : 19 FEB 2009, DOI: 10.1002/jps.21712

  14. You have free access to this content
    Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients

    British Journal of Clinical Pharmacology

    Volume 60, Issue 4, October 2005, Pages: 378–389, K. M. L. Crommentuyn, B. S. Kappelhoff, J. W. Mulder, A. T. A. Mairuhu, E. C. M. Van Gorp, P. L. Meenhorst, A. D. R. Huitema and J. H. Beijnen

    Version of Record online : 19 JUL 2005, DOI: 10.1111/j.1365-2125.2005.02455.x

  15. You have free access to this content
    Enhanced Boosting of Oral Absorption of Lopinavir Through Electrospray Coencapsulation with Ritonavir

    Journal of Pharmaceutical Sciences

    Volume 104, Issue 9, September 2015, Pages: 2977–2985, Shinji Sakuma, Satoshi Matsumoto, Narimoto Ishizuka, Kohta Mohri, Mayuko Fukushima, Chie Ohba and Kohsaku Kawakami

    Version of Record online : 18 MAY 2015, DOI: 10.1002/jps.24492

  16. You have free access to this content
    Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 80, Issue 4, October 2015, Pages: 670–677, Priska Kaufmann, Séverine Niglis, Shirin Bruderer, Jérôme Segrestaa, Päivi Äänismaa, Atef Halabi and Jasper Dingemanse

    Version of Record online : 12 JUN 2015, DOI: 10.1111/bcp.12650

  17. You have free access to this content
    Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor

    British Journal of Clinical Pharmacology

    Volume 57, Issue 4, April 2004, Pages: 436–440, Caroline Solas, Isabelle Poizot-Martin, Marie-Pierre Drogoul, Isabelle Ravaux, Catherine Dhiver, Alain Lafeuillade, Thierry Allegre, Malika Mokhtari, Jacques Moreau, Gérard Lepeu, Nathalie Petit, Alain Durand and Bruno Lacarelle

    Version of Record online : 8 JAN 2004, DOI: 10.1046/j.1365-2125.2003.02020.x

  18. You have free access to this content
    The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach

    HIV Medicine

    Volume 8, Issue 7, October 2007, Pages: 439–450, Y Yazdanpanah, M Vray, J Meynard, E Losina, MC Weinstein, L Morand-Joubert, SJ Goldie, HE Hsu, RP Walensky, C Dalban, PE Sax, PM Girard and KA Freedberg

    Version of Record online : 23 AUG 2007, DOI: 10.1111/j.1468-1293.2007.00491.x

  19. You have full text access to this OnlineOpen article
    Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects

    Clinical Pharmacology in Drug Development

    Volume 6, Issue 1, January/February 2017, Pages: 93–101, Takao Yamazaki, Amit Desai, David Han, Kota Kato, Donna Kowalski, Shahzad Akhtar, Christopher Lademacher, Laura Kovanda and Robert Townsend

    Version of Record online : 20 JUL 2016, DOI: 10.1002/cpdd.282

  20. You have free access to this content
    Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure

    HIV Medicine

    Volume 9, Issue 4, April 2008, Pages: 239–245, S Di Giambenedetto, A De Luca, P Villani, A Bacarelli, E Ragazzoni, M Regazzi, R Cauda and P Navarra

    Version of Record online : 23 MAR 2008, DOI: 10.1111/j.1468-1293.2008.00555.x